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a b s t r a c t
We have identiﬁed a novel 7.7 Mb del(8)(q23.2q24.11) in a patient progressing to acute myeloid
leukemia (AML) following a 12-year stable phase of chronic myelomonocytic leukemia (CMML).
A surprisingly high JAK2þ allelic burden of 92% at the time of AML led us to delineate the molecular
aberrations relevant for leukemogenesis. While a frameshift mutation in the TET2 gene was stably
present throughout the course of disease the JAK2mutation was acquired after initial diagnosis of CMML.
At progression aCGH revealed del(8q)(q23.2q24.11) encompassing various cancer relevant genes of
which RAD21 and CSMD3 are of particular interest.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Chronic myelomonocytic leukemia (CMML) is a clonal
hematopoietic stem cell neoplasm with overlapping myelodys-
plastic and myeloproliferative features. While progression to acute
myeloid leukemia (AML) is common, the driving molecular aber-
rations involved in transformation remain obscure [1]. Clonal
cytogenetic abnormalities predict adverse prognosis and are
evident in up to 40% of cases [2]. Next generation sequencing
has identiﬁed molecular aberrations in approximately 90% of
CMML patients with TET2 gene mutations (TET2þ) being particu-
larly frequent. On the contrary, the JAK2 V617F mutation (JAK2þ)
is uncommon [3]. Concomitant TET2þ and JAK2þ have been
described in chronic myeloproliferative disorders, but none of
these are sufﬁcient to drive blastic transformation. Moreover,
transformation of myeloproliferative disorders most often results
in loss of JAK2þ indicating the transformation to arise in a JAK2-
negative subclone [4]. We here report a case of TET2þ CMML who
acquired JAK2þ and progressed into overt AML 12 years after
initial diagnosis. Array comparative genomic hybridization (aCGH)
revealed a novel del(8q)(q23.2q24.11) (del(8q)) comprising genes
with recently reported relevance in cancer, including AML.
2. Case presentation
In 1998, a 64-year old male presented with pleural effusion,
pericarditis, and leukocytosis of 38109/L with 30% monocytes.
A complete overview of the clinical course of disease is given in
Table 1. A bone marrow (BM) biopsy revealed CMML-1. There was
no splenomegaly or cytopenias. In 2004, pleural effusion ree-
merged and microscopy of pleural ﬂuid revealed numerous CD68
positive monocytes. Lymph node enlargement emerged in 2007
and a biopsy showed inﬁltration of 50% fully differentiated mono-
cytes. Despite these various CMML-related manifestations, no
cytopenias were evident. However, in 2010 BM failure developed
with decreasing hemoglobin and thrombocyte counts and increas-
ing leukocyte count. Morphology revealed persistent CMML-1.
Nine months later, in June 2011 at the age of 76 the patient was
admitted with abdominal pain and severely deranged hematopoi-
esis and was diagnosed with AML. Flow cytometry of peripheral
blood showing 40% myeloblasts staining positive for CD34, CD117,
HLA-DR, and CD13. A CT scan showed splenomegaly, and signs of
malignant inﬁltration in the renal parenchyma and the soft tissue
along the lower thoracic vertebras, suspicious of myelosarcomas.
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The patient received palliative care, but succumbed from progres-
sive renal failure in July 2011.
Routine molecular analysis at AML diagnosis showed a JAK2þ
allelic burden of 92% of mononuclear cells (MNCs) from peripheral
blood (PB). Since JAK2þ is usually lost upon transformation this
led us to retrospectively delineate the longitudinal evolution of
molecular aberrations at critical time points, summarized in
Table 1.
In short, DNAwas extracted from diagnostic parafﬁn embedded
BM biopsies (1998), from thawed BM MNCs from the time of
disease progression (2010), and from PB MNCs at the time of overt
AML (2011). JAK2þ was analyzed for by standard quantitative
polymerase chain reaction (qPCR). While the diagnostic CMML
sample was negative for JAK2þ , the allelic burden was above the
90% level both in the transformation- and AML phase of disease.
The entire coding sequences and all splice sites of the TET2 gene
(exons 3–11) were scanned for mutations by PCR combined with
denaturing gradient gel electrophoresis (DGGE) as described in
Ref. [5]. In all samples, a stable frameshift mutation in exon 6 was
found (c.3658_3658del A, Thr1220fs. RefSeq NM_001127208.2).
DNA extracted from a benign skin biopsy from 1990 proved
negative for TET2 mutations, hence excluding germline mutation
(Fig. 1A). By multiplex ﬂuorescent-labeled PCR followed by capil-
lary gel electrophoresis we retrospectively analyzed MNCs from
the time of AML-diagnosis for recurrent AML related mutations,
namely FLT3-ITD, FLT3-D835, cKIT D816V, IDH1 R132, CEBPA, NPM1
exon 12, and WT1 exon 7 of which all came out negative. Standard
G-band karyotyping was not performed at initial diagnosis in
1998, but the karyotype was 46,XY[20] two and a half years from
diagnosis in stable phase of disease. However, in September 2010
the karyotype had changed to 46,XY,dup(9)(p21p21)[6]/46,XY[19].
Since progressive BM failure was not evident until September
2010, we considered this time point pivotal in AML transforma-
tion. Consequently, we focused on identifying candidate aberra-
tions of potential impact by applying aCGH using human Cancer
CytoChip at this time point. Regions of gain or loss contained
within copy number variable regions (CNVs) were discarded.
Reference genome was NCBI build 36.1 (hg18). High-resolution
aCGH analysis revealed an interstitial deletion in chromosome 8 at
bands q23.2-q24.11 of maximal size 7,7 Mb (position 110.679.916–
118.334.826) (Fig. 1B and C). To conﬁrm this ﬁnding and to
longitudinally analyze for the del(8q), we performed ﬂuorescence
in situ hybridization (FISH) with the following directly labeled
probes: RP11-11A18 (SpectrumOrange-labeled, BlueGnome, Cam-
bridge, UK) located at 8q23.3 (position 113.491.837–113.659.918)
and centromere SE 8 probe (FITC-labeled, Kreatech, Amsterdam,
The Netherlands). Chromosomes and nuclei were counterstained
with 40,6-diamidino-2-phenylindole dihydrochloride. The FISH
analysis conﬁrmed the presence of del(8q) in the progression-
and AML phase and absence of del(8q) in the stable phase of
CMML in 2001 (Fig. 1D). Array CGH did not detect the dup(9)
(p21p21) found with standard G-banding karyotyping in Septem-
ber 2010, since the fraction of dup(9) positive cells is below the
sensitivity of aCGH.
The region 8q23.2-q24.11 encompasses genes as depicted in
Fig. 1C. We performed an NCBI gene database and PubMed search
on each of these genes for their reported relevance in carcinogen-
esis. Importantly, several of these are of notiﬁed relevance; TRPS1
and EIF3H are reported as candidate oncogenes with increased
expression in breast cancer [6,7]. In a study of non-small cell lung
carcinomas the CUB and sushi multiple domains 3 gene (CSMD3)
was identiﬁed as the second most frequently mutated gene and
loss of function cause increased proliferation of airway epithelial
cells in vitro [8]. While the CSMD gene family has recently been
suggested tumor suppressor genes in colorectal cancer [9], the role
of CSMD3 in hematological cancers remains to be elucidated.
Strikingly, RAD21 has been associated with AML as it encodes a
protein in the cohesin complex, which is involved in chromosome
segregation during cell division, regulation of transcription, and
DNA double strand break repair. Recently, genes belonging to the
cohesin complex were described as novel recurrent and mutually
exclusive mutations in myeloid neoplasms [10].
Table 1
Longitudinal registration of disease stage, laboratory values, cytogenetic and molecular analyses.
December 1998 June 2001 September 2010 June 2011
Clinical features Pericarditis and pleuritis Routine follow-up Progressive BM failure BM failure, splenomegaly,
and possible myelosarcoma
Lab results
Hemoglobin (mmol/L) 7.9 8.5 5.1 5.3
Platelets (109/L) 206 241 218 25
Leukocytes (109/L) 23.7 33.9 55.5 84.2
Neutrophils (109/L) 12.6 8.8 46.6 61.5
Monocytes (109/L) 5.45 18.6 3.03 4.21
Morphology CMML-1 CMML-1 CMML-1 Dry tap, inconclusive
Blasts incl. promonocytes in BM o5% o5% o5% 20%a
Flow cytometry ND ND CMML (BM) AML (PB)
3% CD34þCD117þmyeloblasts 40% CD34þCD117þmyeloblasts
84% CD64þmyelomonocytoid cells 10% co-expression of CD64
G-banding ND 46,XY[20] 46,XY,dup(9)(p21p21)[6]/46,XY[19] 45,X–Y[5]/46,XY[20]
TET2 mutation Positive ND Positive Positive
JAK2 mutation Negative ND 93% of BM MNCs 92% of PB MNCs
Array CGH ND ND del(8)(q23.2q24.11) ND
Interphase nuclei FISH ND BM BM PB
Neg. for del(8q) 88% cells with del(8q) 15% cells with del(8q)
BM: bone marrow; ND: not done; PB: peripheral blood; MNCs: mononuclear cells.
a Blast count in PB, due to dry tap.
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3. Conclusion
We have longitudinally described the molecular aberrations
present at critical time points from initial diagnosis of CMML to
overt AML applying a comprehensive panel of molecular analyses.
Firstly, the consistent and non-germ line TET2þ in all stages of
disease verify that the AML stage indeed was transformed from
CMML and not a de novo event. Secondly, in this case, TET2þ and
JAK2þ represent founder mutations. It cannot be ruled out that
the massive JAK2þ allelic burden have contributed to genomic
instability and, speculatively, also inﬂuenced the proliferative
potential of the leukemic blasts. Thirdly, aCGH revealed a novel
del(8q). Our results indicate that the leukemic transformation of
an otherwise long-standing and stable CMML could have been
driven by loss of gene function resulting from this exact deletion.
Of the deleted genes, RAD21 and CSMD3 are of particular interest,
since their loss of function have recently been reported to play a
role in carcinogenesis. However, their role in hematological
cancers remains to be studied. Finally, this case report emphasizes
the relevance of aCGH in the search for candidate genes involved
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Fig. 1. Output data of applied analyses. (A) DGGE analysis showing mutant TET2 being present in all samples as indicated by the heteroduplex band (arrow) (1). Sanger
sequencing of the heteroduplex band showing presence of both mutant (del A) and normal alleles (reverse strand shown) (2). (B) High-resolution aCGH analysis at the time
of progressive BM failure in 2010 revealing a submicroscopic deletion at chromosome 8 (arrow). The X-axis at the bottom denotes the chromosomal position. (C) Zoom view
of genomic proﬁle at chromosome 8 showing the deleted region 8q23.2–24.11 as indicated by red shade on chromosome 8 ideogram. The genes located in the deleted region
are listed. Locations of BAC probes for subsequent FISH are indicated (red and green bars). (D) Conﬁrmatory FISH using BAC probe RP11-11A18 at 8q23.3 in the CSMD3 gene
(red) and centromeric SE 8 probe (green) showing the deletion on one chromosome 8 (red arrows) in metaphases and interphase nuclei (1R2G signal pattern). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
M. Toft-Petersen et al. / Leukemia Research Reports 3 (2014) 94–9796
in leukemogenesis, not least in heterogeneous neoplasms such
as CMML.
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